How to manage polycythemia vera
نویسندگان
چکیده
منابع مشابه
How I Treat How I treat polycythemia vera
I will take advantage of the history of two gentlemen that I encountered in the office some years apart to illustrate how I manage subjects referred for the investigation of erythrocytosis and are then found to have polycythemia vera (PV) rather than relative or secondary erythrocytosis (Table 1). Therefore, this manuscript is not intended to provide a thorough description of the disease or to ...
متن کاملHow I treat How I treat polycythemia vera
Polycythemia vera (PV) is a clonal disorder characterized by unwarranted production of red blood cells. In the majority of cases, PV is driven by oncogenic mutations that constitutively activate the JAKSTAT signal transduction pathway, such as JAK2 V617F, or exon 12 mutations or LNK mutations. Diagnosis of PV is based on the WHO criteria. Diagnosis of post-PV myelofibrosis is established accord...
متن کاملP35: How to Manage Anxiety
Anxiety is a mental state that is elicited in anticipation of threat or potential threat. Sensations of anxiety are a normal part of human experience, but excessive or inappropriate anxiety can become an illness. Anxiety is part of the normal human experience. We may speculate that it served human survival during evolution by enhancing preparedness and alertness. However, anxious manifestations...
متن کاملTreatment of polycythemia vera.
BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...
متن کاملPathogenesis of polycythemia vera.
BACKGROUND AND OBJECTIVE Polycythemia vera (PV) is an acquired clonal myeloproliferative disorder characterized by increased production of mature red cells. We still lack a molecular target responsible for this disorder; however, recent investigations have focused on a number of molecules involved in signal transduction pathways mediated by erythropoietin (Epo) and other growth factors. Here we...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2011
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2011.334